Coloplast A/S Q3 2026 Earnings Recap

CLPBY Q3 2026 August 20, 2026

Get alerts when CLPBY reports next quarter

Shares rose 6.1% as Coloplast reassured investors with sustained leadership positions, a strong product portfolio, and clear strategic priorities to drive growth, particularly emphasizing growth potential in the U.S. market.

Earnings Per Share Beat

$0.10 vs $0.10 est.

+0.0% surprise

Revenue Beat

1139462000 vs 1114016000 est.

+2.3% surprise

Market Reaction

1-Day +0.88%

5-Day +6.16%

See CLPBY alongside your other holdings

Add to your portfolio — free

Key Takeaways

Chronic Care remains the core segment, representing over 75% of sales, with continued leadership and an annuity-based business model reinforcing revenue stability.
U.S. market highlighted as a significant growth opportunity, currently under-penetrated with market shares of 15-20% in Ostomy Care and about 30% in Continence Care.
Biologics segment in Wound & Tissue Repair faces challenges due to a recent U.S. market reset but focusing on inpatient care and clinical differentiation to restore profitable growth.
New CEO Gavin Wood is prioritizing disciplined capital allocation, investment governance, and innovation pipeline to accelerate growth and extend competitive moats.
Leadership changes include appointing a new Chief People Officer and executive realignment in Wound & Tissue Repair to strengthen organizational focus and execution.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CLPBY on AllInvestView.